Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy

Phase 2

Terminated

• Conditions: Hypertriglyceridemia

• Registration Number: NCT00080132
• Lead Sponsor: Medical Research Laboratories International

Brief Summary

The purpose of this study is to determine if implitapide is effective in lowering triglyceride (TG) levels in patients with Fredrickson Type I or V hypertriglyceridemia where the maximum tolerable medication and diet were not sufficient.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2004-03-23
• Study First Submitted QC: 2004-03-24
• Study First Posted: 2004-03-25
• Study Start: 2004-10
• Status Verified: 2005-04
• Study Completion: 2005-04
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

In order to participate in this study, patients must meet all of the following inclusion criteria:

• be between 8 and 70 years old with diagnosis of Fredrickson Type I or V HTG
• be stable on current maximum tolerated triglyceride lowering therapy
• have a fasting TG level of at least 880 mg/dL (10 mmol/L)
• be male or nonpregnant, nonbreastfeeding female. The women in the study must be surgically sterile, postmenopausal or must practice an effective method of birth control
• must be able to give informed consent or if under the age of 18, parents or legal guardians must give their informed consent
• meet body weight requirements

Exclusion Criteria

• Recent heart attack, coronary artery intervention, coronary bypass surgery, or stroke.
• Patients with class 3 or 4 heart failure
• Uncontrolled hypothyroidism or other uncontrolled endocrine disease
• Known, clinically significant eye abnormalities, such as cataracts
• History of hepatic disease or AST or ALT levels greater than 1.5 x ULN at Visit 1
• Alkaline phosphatase greater than 2 times ULN
• Serum creatinine greater than 2.0 mg/dL
• Liver cirrhosis and severe liver steatosis
• Clinically significant infection, malignancy, or psychosis
• Use of oral anticoagulants or digoxin unless the dose is stable and is regularly monitored
• Participation in any other investigational study within the last 30 days
• Breastfeeding or pregnant
• Current drug or alcohol abuse
• Serious or unstable medical conditions that would compromise the patient's safety or successful participation in the study
• Unwillingness to comply with study procedures or unwillingness to cooperate fully

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (9)

The Methodist Hospital; 🇺🇸 Houston, Texas, United States

Andromed Rotterdam; 🇳🇱 Rotterdam, Netherlands

Andromed Zoetermeer; 🇳🇱 Zoetermeer, Netherlands

Lipidklinikken - Rikshospitalet; 🇳🇴 Oslo, Norway

Metabolic and Atherosclerosis Research Center; 🇺🇸 Cincinnati, Ohio, United States

Andromed Leiden; 🇳🇱 Leiden, Netherlands

Andromed Noord; 🇳🇱 Groningen, Netherlands

Academic Medical Center Amsterdam; 🇳🇱 Amsterdam, Netherlands

Andromed Oost; 🇳🇱 Velp, Netherlands